Rekah Pharmaceutical Industry (REKA) Stock Overview
Engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
REKA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Rekah Pharmaceutical Industry Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪11.02 |
| 52 Week High | ₪13.97 |
| 52 Week Low | ₪10.44 |
| Beta | 0.14 |
| 1 Month Change | -7.55% |
| 3 Month Change | -10.84% |
| 1 Year Change | -11.84% |
| 3 Year Change | -35.82% |
| 5 Year Change | -53.66% |
| Change since IPO | -96.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| REKA | IL Pharmaceuticals | IL Market | |
|---|---|---|---|
| 7D | -0.5% | -0.8% | -6.1% |
| 1Y | -11.8% | -37.0% | 45.6% |
Return vs Industry: REKA exceeded the IL Pharmaceuticals industry which returned -37.8% over the past year.
Return vs Market: REKA underperformed the IL Market which returned 48.7% over the past year.
Price Volatility
| REKA volatility | |
|---|---|
| REKA Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in IL Market | 8.9% |
| 10% least volatile stocks in IL Market | 3.7% |
Stable Share Price: REKA has not had significant price volatility in the past 3 months compared to the IL market.
Volatility Over Time: REKA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 390 | Mordechai Elgrabli | www.rekah.co.il |
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. The company offers steroids, antibiotics, and ophthalmic products, as well as dermo-cosmetics products. Its portfolio of products comprise Rx and OTC drugs, and medical devices used in various therapeutic fields, such as urinary tract pain, steroid anti-inflammatories, cough, expectoration and bronchitis, motion sickness, runny nose and congestion, skin disinfection, wounds, burns and insect bites, eye infections, glaucoma, dryness, allergies, fever and pain relief, mouth, depression and anxiety, muscle and joint pain, antibiotics, fungal infections, anemia and nutritional deficits, ear pain, babies and children, etc. The company was founded in 1947 and is based in Holon, Israel.
Rekah Pharmaceutical Industry Ltd. Fundamentals Summary
| REKA fundamental statistics | |
|---|---|
| Market cap | ₪125.79m |
| Earnings (TTM) | -₪18.07m |
| Revenue (TTM) | ₪300.99m |
Is REKA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REKA income statement (TTM) | |
|---|---|
| Revenue | ₪300.99m |
| Cost of Revenue | ₪231.42m |
| Gross Profit | ₪69.57m |
| Other Expenses | ₪87.64m |
| Earnings | -₪18.07m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.58 |
| Gross Margin | 23.11% |
| Net Profit Margin | -6.00% |
| Debt/Equity Ratio | 65.0% |
How did REKA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/15 11:13 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rekah Pharmaceutical Industry Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.